Atazanavir
- Generic Name
- Atazanavir
- Brand Names
- Evotaz, Reyataz, Atazanavir Krka, Atazanavir Viatris (previously Atazanavir Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C38H52N6O7
- CAS Number
- 198904-31-3
- Unique Ingredient Identifier
- QZU4H47A3S
- Background
Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the pa...
- Indication
Atazanavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older weighing at least 5kg. Atazanavir is also indicated in combination with cobicistat and other antiretrovirals for the treatment of HIV-1 infection in adults and pediatric patients weighing at l...
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
ATAGLU: Study of Glucose Metabolism in HIV Positive Patients That Switch From Another Protease Inhibitor to Atazanavir
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 300
- Registration Number
- NCT02102048
- Locations
- 🇮🇹
Department of Public Heath and Infectious Diseases. University of Rome "Sapienza" (Italy), Rome, Italy
Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts
- Conditions
- Interventions
- First Posted Date
- 2013-08-26
- Last Posted Date
- 2018-01-12
- Target Recruit Count
- 120
- Registration Number
- NCT01928407
- Locations
- 🇫🇷
Hopital Saint Antoine, Paris, France
🇫🇷Hopital Le Bocage, Dijon, France
🇫🇷C.H.D de Vendee, La Roche Sur Yon, France
A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 499
- Registration Number
- NCT01910402
- Locations
- 🇬🇧
GSK Investigational Site, Tooting, London, United Kingdom
Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat
- Conditions
- Interventions
- First Posted Date
- 2013-04-23
- Last Posted Date
- 2014-08-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 64
- Registration Number
- NCT01837719
- Locations
- 🇺🇸
Ppd Development, Inc., Austin, Texas, United States
Study to Evaluate a HIV Drug for the Treatment of HIV Infection
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 107
- Registration Number
- NCT01803074
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2018-04-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 108
- Registration Number
- NCT01691794
- Locations
- 🇺🇸
Children'S Medical Center Of Dallas, Dallas, Texas, United States
🇺🇸Phoenix Children'S Hospital, Phoenix, Arizona, United States
🇿🇦Local Institution, Cape Town, Western CAPE, South Africa
Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC
- Conditions
- Interventions
- First Posted Date
- 2012-06-15
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 3
- Registration Number
- NCT01620944
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
- Conditions
- Interventions
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT01605084
- Locations
- 🇺🇸
Anthony M. Mills Md Inc, Los Angeles, California, United States
🇺🇸Metropolis Medical Pc, San Francisco, California, United States
🇺🇸Be Well Medical Center, Berkley, Michigan, United States
A Study of Drug-Drug Interaction Between Danoprevir Coadministered With Low-Dose Ritonavir and Tenofovir Disoproxil Fumarate or Atazanavir
- Conditions
- Interventions
- First Posted Date
- 2012-05-07
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT01592305
A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2012-05-04
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 51
- Registration Number
- NCT01591850
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.